Search Results (23)

Objectives: Using high-performance liquid chromatography (HPLC), we developed and validated an in vitro assay for the quantitative determination of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) activity, supplementing limited current methodologies to assess the efficacy of BACE1 inhibitor compounds. A hexa-histidine tagged peptide substrate of BACE1 was used as the analyte for the determination of in vitro BACE1 activity; it was validated according to ICH guidelines. Methods: The HPLC analysis was performed on the Agilent 1290 Series Infinity II UHPLC System equipped with a Phenomenex Kinetex EVO C18 (100 × 3 mm) 5 µm column. The method was developed using a gradient programme comprising 10% aqueous acetonitrile (0.02 M TFA) to 30% aqueous acetonitrile (0.02 M TFA) for 5 min at a flow rate of 0.6 mL/min. Results: The method showed linearity over the range of 14.92 to 72 µM with ${\mathrm{r}}^2=0.9997$. The accuracy of the method in terms of mean recovery ranged between 96.62 and 98.38%. The %RSD for intra- and inter-day precision was less than 5%. Two commercial inhibitors, AZD3839 and OM99-2, were used to evaluate the performance of the method at their respective IC₅₀, resulting in inhibition of 53.46 and 50.74%, respectively. The described method addresses the void for a practical and cheap alternative to quantitatively determine the activity of BACE1 compared to current commercially available detection assays. Conclusions: We have successfully developed an HPLC method to measure the inhibitory function of two commercial inhibitors of BACE1, indicating the suitability of the method for the identification and characterisation of novel BACE1 inhibitors. Full article

Alzheimer’s disease is characterized, in part, by the accumulation of β-amyloid (Aβ) in the brain. Aβ is produced via the proteolysis of APP by BACE1 and γ-secretase. Since BACE1 is the rate-limiting enzyme in the production of Aβ, and a target for therapeutics, it is of interest to know when its proteolytic function evolved and for what purpose. Here, we take a functional evolutionary approach to show that BACE1 likely evolved from a gene duplication event near the base of the animal clade and that BACE1 APP/Aβ proteolytic function evolved during early animal diversification, hundreds of millions of years before the evolution of the APP/Aβ substrate. Our examination of BACE1 APP/Aβ proteolytic function includes cnidarians, ctenophores, and choanoflagellates. The most basal BACE1 ortholog is found in cnidarians, while ctenophores, placozoa, and choanoflagellates have genes equally orthologous to BACE1 and BACE2. BACE1 from a cnidarian (Hydra) can cleave APP to release Aβ, pushing back the date of the origin of its function to near the origin of animals. We tested more divergent BACE1/2 genes from a ctenophore (Mnemiopsis) and a choanoflagellate (Monosiga), and neither has this activity. These findings indicate that the specific proteolytic function of BACE1 evolved during the very earliest diversification of animals, most likely after a gene-duplication event. Full article

β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is considered a therapeutic target to combat Alzheimer’s disease by reducing β-amyloid in the brain. To date, all clinical trials involving the inhibition of BACE1 have been discontinued due to a lack of efficacy or undesirable side effects such as cognitive worsening. The latter could have been the result of the inhibition of BACE at the synapse where it is expressed in high amounts. We have previously shown that prolonged inhibition of BACE interferes with structural synaptic plasticity, most likely due to the diminished processing of the physiological BACE substrate Seizure protein 6 (Sez6) which is exclusively processed by BACE1 and is required for dendritic spine plasticity. Given that BACE1 has significant amino acid similarity with its homolog BACE2, the inhibition of BACE2 may cause some of the side effects, as most BACE inhibitors do not discriminate between the two. In this study, we used newly developed BACE inhibitors that have a different chemotype from previously developed inhibitors and a high selectivity for BACE1 over BACE2. By using longitudinal in vivo two-photon microscopy, we investigated the effect on dendritic spine dynamics of pyramidal layer V neurons in the somatosensory cortex in mice treated with highly selective BACE1 inhibitors. Treatment with those inhibitors showed a reduction in soluble Sez6 (sSez6) levels to 27% (elenbecestat, Biogen, Eisai Co., Ltd., Tokyo, Japan), 17% (Shionogi compound 1) and 39% (Shionogi compound 2), compared to animals fed with vehicle pellets. We observed a significant decrease in the number of dendritic spines with Shionogi compound 1 after 21 days of treatment but not with Shionogi compound 2 or with elenbecestat, which did not show cognitive worsening in clinical trials. In conclusion, highly selective BACE1 inhibitors do alter dendritic spine density similar to non-selective inhibitors if soluble (sSez6) levels drop too much. Low-dose BACE1 inhibition might be reasonable if dosing is carefully adjusted to the amount of Sez6 cleavage, which can be easily monitored during the first week of treatment. Full article

The amyloidogenic processing of APP depends on two events: its phosphorylation by ROCK2 (at Thr654) and the phosphorylation of the APP-cleaving enzyme BACE1 (at Ser498). However, the mechanisms and structural details of APP-ROCK2 and BACE1-ROCK2 binding are unknown. Using direct physical methods in combination with an in silico approach, we found that BACE1 binds into the substrate-binding groove of ROCK2 with a low affinity (K_d = 18 µM), while no binding of APP to ROCK2 alone could be detected. On the other hand, a strong association (K_d = 3.5 nM) of APP to the weak ROCK2-BACE1 complex was observed, although no stable ternary complex was detected, i.e., BACE1 was displaced by APP. We constructed a sequential functional model: (1) BACE1 weakly binds to ROCK2 and induces an allosteric conformational change in ROCK2; (2) APP strongly binds to the ROCK2-BACE1 complex, and BACE1 is released; and (3) ROCK2 phosphorylates APP at Thr654 (leading to a longer stay in the early endosome during APP processing). Direct fluorescence titration experiments showed that the APP_646–664 or APP_665–695 fragments did not bind separately to the ROCK2-BACE1 complex. Based on these observations, we conclude that two binding sites are involved in the ROCK2-APP interaction: (1) the substrate-binding groove, where the APP_646–664 sequence containing Thr654 sits and (2) the allosteric binding site, where the APP_665–695 sequence binds. These results open the way to attack the allosteric site to prevent APP phosphorylation at Thr654 by ROCK2 without inhibiting the activity of ROCK2 towards its other substrates. Full article

The strategy to increase the performance of the single solid oxide fuel cell (SOFC) with a supporting membrane of Ce_0.8Sm_0.2O_1.9 (SDC) electrolyte has been implemented in this study by introducing a thin anode barrier layer of the BaCe_0.8Sm_0.2O₃ + 1 wt% CuO (BCS-CuO) electrolyte and, additionally, a modifying layer of a Ce_0.8Sm_0.1Pr_0.1O_1.9 (PSDC) electrolyte. The method of electrophoretic deposition (EPD) is used to form thin electrolyte layers on a dense supporting membrane. The electrical conductivity of the SDC substrate surface is achieved by the synthesis of a conductive polypyrrole sublayer. The kinetic parameters of the EPD process from the PSDC suspension are studied. The volt-ampere characteristics and power output of the obtained SOFC cells with the PSDC modifying layer on the cathode side and the BCS-CuO blocking layer on the anode side (BCS-CuO/SDC/PSDC) and with a BCS-CuO blocking layer on the anode side (BCS-CuO/SDC) and oxide electrodes have been studied. The effect of increasing the power output of the cell with the BCS-CuO/SDC/PSDC electrolyte membrane due to a decrease in the ohmic and polarization resistances of the cell is demonstrated. The approaches developed in this work can be applied to the development of SOFCs with both supporting and thin-film MIEC electrolyte membranes. Full article

In the present energetic scenario, the development of materials with high potentiality in the technological fields of energy conversion processes, production and storage of hydrogen, are of great interest in the scientific community. In particular, we report for the first time the fabrication of crystalline and homogeneous barium-cerate-based materials in the form of thin films on various substrates. Starting from the β-diketonate precursor sources Ce(hfa)₃diglyme, Ba(hfa)₂tetraglyme and Y(hfa)₃diglyme (Hhfa = 1,1,1,5,5,5-hexafluoroacetylacetone; diglyme = bis(2-methoxyethyl)ether; tetraglyme = 2,5,8,11,14-pentaoxapentadecane), a metalorganic chemical vapor deposition (MOCVD) approach has been successfully applied to the fabrication of BaCeO₃ and doped BaCe_0.8Y_0.2O₃ systems in the form of thin films. Structural, morphological and compositional analyses allowed for an accurate determination of the properties of deposited layers. The present approach represents a simple, easily scalable, and industrially appealing process for the production of compact and homogeneous barium cerate thin films. Full article

Quercetin has been studied extensively for its anti-Alzheimer’s disease (AD) and anti-aging effects. Our previous studies have found that quercetin and in its glycoside form, rutin, can modulate the proteasome function in neuroblastoma cells. We aimed to explore the effects of quercetin and rutin on intracellular redox homeostasis of the brain (reduced glutathione/oxidized glutathione, GSH/GSSG), its correlation with β-site APP cleaving enzyme 1 (BACE1) activity, and amyloid precursor protein (APP) expression in transgenic TgAPP mice (bearing human Swedish mutation APP transgene, APPswe). On the basis that BACE1 protein and APP processing are regulated by the ubiquitin–proteasome pathway and that supplementation with GSH protects neurons from proteasome inhibition, we investigated whether a diet containing quercetin or rutin (30 mg/kg/day, 4 weeks) diminishes several early signs of AD. Genotyping analyses of animals were carried out by PCR. In order to determine intracellular redox homeostasis, spectrofluorometric methods were adopted to quantify GSH and GSSG levels using o-phthalaldehyde and the GSH/GSSG ratio was ascertained. Levels of TBARS were determined as a marker of lipid peroxidation. Enzyme activities of SOD, CAT, GR, and GPx were determined in the cortex and hippocampus. ΒACE1 activity was measured by a secretase-specific substrate conjugated to two reporter molecules (EDANS and DABCYL). Gene expression of the main antioxidant enzymes: APP, BACE1, a Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10), caspase-3, caspase-6, and inflammatory cytokines were determined by RT-PCR. First, overexpression of APPswe in TgAPP mice decreased GSH/GSSG ratio, increased malonaldehyde (MDA) levels, and, overall, decreased the main antioxidant enzyme activities in comparison to wild-type (WT) mice. Treatment of TgAPP mice with quercetin or rutin increased GSH/GSSG, diminished MDA levels, and favored the enzyme antioxidant capacity, particularly with rutin. Secondly, both APP expression and BACE1 activity were diminished with quercetin or rutin in TgAPP mice. Regarding ADAM10, it tended to increase in TgAPP mice with rutin treatment. As for caspase-3 expression, TgAPP displayed an increase which was the opposite with rutin. Finally, the increase in expression of the inflammatory markers IL-1β and IFN-γ in TgAPP mice was lowered by both quercetin and rutin. Collectively, these findings suggest that, of the two flavonoids, rutin may be included in a day-to-day diet as a form of adjuvant therapy in AD. Full article

In this work, a technology was developed for the formation of BaCe_0.8Sm_0.2O₃+1 wt% CuO (BCS-CuO)/Ce_0.8Sm_0.2O_1.9 (SDC) thin-film electrolyte membranes for intermediate-temperature solid oxide fuel cells (IT-SOFCs) on porous NiO-BCS-CuO anode substrates using direct electrophoretic deposition (EPD). The effect of increasing the zeta potential when modifying the base suspension of a micro-sized SDC-gn powder (glycine–nitrate method) with the addition of a SDC-lec nanopowder (laser evaporation–condensation) was investigated. Dependences of the current strength on the deposition time and the deposited weight on the EPD voltage were obtained, and evolution of the morphology of the coatings during the modification of the SDC-gn suspension and a suspension of BCS-CuO powder was studied. The compatibility of the shrinkage kinetics of the SDC, the BCS-CuO electrolyte coatings and the NiO-BCS-CuO anode substrate was studied during the high-temperature sintering. Dense BCS-CuO/SDC films of different thicknesses were obtained for the first time on porous NiO-BCS-CuO anode substrates and comprehensive microstructural and electrochemical studies were carried out. The developed technology can be applied to the formation of anode-supported SOFCs with thin-film electrolyte membranes. Full article

The β-site Amyloid precursor protein Cleaving Enzyme 1 (BACE1) is an extensively studied therapeutic target for Alzheimer’s disease (AD), owing to its role in the production of neurotoxic amyloid beta (Aβ) peptides. However, despite numerous BACE1 inhibitors entering clinical trials, none have successfully improved AD pathogenesis, despite effectively lowering Aβ concentrations. This can, in part, be attributed to an incomplete understanding of BACE1, including its physiological functions and substrate specificity. We propose that BACE1 has additional important physiological functions, mediated through substrates still to be identified. Thus, to address this, we computationally analysed a list of 533 BACE1 dependent proteins, identified from the literature, for potential BACE1 substrates, and compared them against proteins differentially expressed in AD. We identified 15 novel BACE1 substrates that were specifically altered in AD. To confirm our analysis, we validated Protein tyrosine phosphatase receptor type D (PTPRD) and Netrin receptor DCC (DCC) using Western blotting. These findings shed light on the BACE1 inhibitor failings and could enable the design of substrate-specific inhibitors to target alternative BACE1 substrates. Furthermore, it gives us a greater understanding of the roles of BACE1 and its dysfunction in AD. Full article

In this study, the technology of electrophoretic deposition (EPD) micrometer barrier layers based on a BaCe_0.8Sm_0.19Cu_0.1O₃ (BCSCuO) protonic conductor on dense carrying Ce_0.8Sm_0.2O_1.9 (SDC) solid-state electrolyte substrates is developed. Methods for creating conductive sublayers on non-conductive SDC substrates under EPD conditions, such as the synthesis of a conductive polypyrrole (PPy) layer and deposition of a layer of finely dispersed platinum from a suspension of its powder in isopropanol, are proposed. The kinetics of disaggregation, disperse composition, electrokinetic potential, and the effect of adding iodine to the BCSCuO suspension on these parameters as factors determining the preparation of stable suspensions and successful EPD processes are explored. Button cells based on a carrying SDC electrolyte of 550 μm in thickness with BCSCuO layers (8–35 μm) on the anode, cathode, and anode/cathode side, and Pt electrodes are electrochemically tested. It was found that the effect of blocking the electronic current in the SDC substrate under OCV conditions was maximal for the cells with barrier layers deposited on the anode side. The technology developed in this study can be used to fabricate solid oxide fuel cells with doped CeO₂ electrolyte membranes characterized by mixed ionic–electronic conductivity (MIEC) under reducing atmospheres. Full article

BACE1 is a key enzyme facilitating the generation of neurotoxic β-amyloid (Aβ) peptide. However, given that BACE1 has multiple substrates we explored the importance of BACE1 in the maintenance of retinal pigment epithelial (RPE) cell homeostasis under oxidative stress. Inhibition of BACE1 reduced mitochondrial membrane potential, increased mitochondrial fragmentation, and increased cleaved caspase-3 expression in cells under oxidative stress. BACE1 inhibition also resulted in significantly lower levels of mitochondrial fusion proteins OPA1 and MFN1 suggesting a higher rate of mitochondrial fission while increasing the levels of mitophagic proteins Parkin and PINK1 and autophagosome numbers. In contrast, BACE2 had minimal effect on cellular response to oxidative stress. In summary, our results emphasize the importance of BACE1 in augmenting cellular defense against oxidative stress by protecting mitochondrial dynamics. Full article

In this work, the challenges associated with the formation of single and bilayer coatings based on Ce_0.8Sm_0.2O_1.9 (SDC) and CuO modified BaCe_0.5Zr_0.3Y_0.1Yb_0.1O_3−δ (BCZYYbO-CuO) solid state electrolytes on porous non-conducting NiO-SDC anode substrates by the method of electrophoretic deposition (EPD) are considered. Various approaches that had been selected after analysis of the literature data in order to carry out the EPD, are tested: direct deposition on a porous non-conductive anode substrate and multiple options for creating the conductivity of the anode substrate under EPD conditions such as the reduction of the NiO-SDC substrate and the creation of a surface conducting sublayer via synthesizing a polypyrrole (PPy) film. New effective method was proposed based on the deposition of a platinum layer on the front side of the substrate. It was ascertained that, during the direct EPD on the porous NiO-SDC substrate, the formation of a continuous coating did not occur, which may be due to insufficient porosity of the substrate used. It was shown that the use of reduced substrates leads to cracking and, in some cases, to the destruction of the entire SDC/NiO-SDC structure. The dependence of the electrolyte film sinterability on the substrate shrinkage was studied. In contrast to the literature data, the use of the substrates with a reduced pre-sintering temperature had no pronounced effect on the densification of the SDC electrolyte film. It was revealed that complete sintering of the SDC electrolyte layer with the formation of a developed grain structure is possible at a temperature of 1550 °C. Full article

Layered Ruddlesden-Popper (RP) lanthanide nickelates, Ln_n+1Ni_nO_3n+1 (Ln = La, Pr, and Nd; n = 1, 2, and 3) have generated great interest as potential cathodes for proton conducting fuel cells (PCFCs). The high-order phase (n = 3) is especially intriguing, as it possesses the property of a high and metallic-type electronic conductivity that persists to low temperatures. To provide the additional requirement of high ionic conductivity, a composite electrode is here suggested, formed by a combination of La₄Ni₃O_10±δ with the proton conducting phase BaCe_0.9Y_0.1O_3-δ (40 vol%). Electrochemical impedance spectroscopy (EIS) is used to analyse this composite electrode in both wet (p_H2O ~ 10⁻² atm) and low humidity (p_H2O ~ 10⁻⁵ atm) conditions in an O₂ atmosphere (400–550 °C). An extended analysis that first tests the stability of the impedance data through Kramers-Kronig and Bayesian Hilbert transform relations is outlined, that is subsequently complemented with the distribution function of relaxation times (DFRTs) methodology. In a final step, correction of the impedance data against the short-circuiting contribution from the electrolyte substrate is also performed. This work offers a detailed assessment of the La₄Ni₃O_10±δ-BaCe_0.9Y_0.1O_3-δ composite cathode, while providing a robust analysis methodology for other researchers working on the development of electrodes for PCFCs. Full article

This paper presents the study of electrophoretic deposition (EPD) of a proton-conducting electrolyte of BaCe_0.89Gd_0.1Cu_0.01O_3-δ (BCGCuO) on porous cathode substrates of LaNi_0.6Fe_0.4O_3−δ (LNFO) and La_1.7Ba_0.3NiO_4+δ (LBNO). EPD kinetics was studied in the process of deposition of both a LBNO sublayer on the porous LNFO substrate and a BCGCuO electrolyte layer. Addition of iodine was shown to significantly increase the deposited film weight and decrease the number of EPD cycles. During the deposition on the LNFO cathode, Ba preservation in the electrolyte layer after sintering at 1450 °C was achieved only with a film thickness greater than 20 μm. The presence of a thin LBNO sublayer (10 μm) did not have a pronounced effect on the preservation of Ba in the electrolyte layer. When using the bulk LBNO cathode substrate as a Ba source, Ba was retained in a nominal amount in the BCGCuO film with a thickness of 10 μm. The film obtained on the bulk LBNO substrate, being in composition close to the nominal composition of the BCGCuO electrolyte, possessed the highest electrical conductivity among the films deposited on the various cathode substrates. The technology developed is a base step in the adaptation of the EPD method for fabrication of cathode-supported Solid Oxide Fuel Cells (SOFCs) with dense barium-containing electrolyte films while maintaining their nominal composition and functional characteristics. Full article

Neuronal insulin resistance is a significant feature of Alzheimer’s disease (AD). Accumulated evidence has revealed the possible neuroprotective mechanisms of antidiabetic drugs in AD. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog and an antidiabetic agent, has a benefit in improving a peripheral insulin resistance. However, the neuronal effect of liraglutide on the model of neuronal insulin resistance with Alzheimer’s formation has not been thoroughly investigated. The present study discovered that liraglutide alleviated neuronal insulin resistance and reduced beta-amyloid formation and tau hyperphosphorylation in a human neuroblostoma cell line, SH-SY5Y. Liraglutide could effectively reverse deleterious effects of insulin overstimulation. In particular, the drug reversed the phosphorylation status of insulin receptors and its major downstream signaling molecules including insulin receptor substrate 1 (IRS-1), protein kinase B (AKT), and glycogen synthase kinase 3 beta (GSK-3β). Moreover, liraglutide reduced the activity of beta secretase 1 (BACE-1) enzyme, which then decreased the formation of beta-amyloid in insulin-resistant cells. This indicated that liraglutide can reverse the defect of phosphorylation status of insulin signal transduction but also inhibit the formation of pathogenic Alzheimer’s proteins like Aβ in neuronal cells. We herein provided the possibility that the liraglutide-based therapy may be able to reduce such deleterious effects caused by insulin resistance. In view of the beneficial effects of liraglutide administration, these findings suggest that the use of liraglutide may be a promising therapy for AD with insulin-resistant condition. Full article